Seroba’s investee company, Quanta Dialysis Technologies Ltd, a medical device company providing innovative haemodialysis solutions for the clinic and the home, has unveiled at the 10th UK Annual Dialysis Conference in Manchester, UK, its SC+ personal haemodialysis system for market launch next year.
Based on clinical experience obtained during Quanta’s extensive pilot studies, which included over 1,100 successful patient treatments at four NHS Trusts across the UK, the Company has optimised SC+ for commercial launch. In addition to the small, simple-to-use and powerful features that already set SC+ apart from traditional dialysis machines, Quanta is introducing state-of-the-art technology enhancements that include a new user interface featuring a high-resolution screen and improved touch functionality, improvements for usability and capabilities to integrate with digital health solutions.
John E. Milad, Chief Executive Officer of Quanta, commented: “We are excited to unveil our launch-product at this important conference for home dialysis. We have listened to the feedback gained from patients, clinicians and nurses during our piloting with the NHS in the UK, and we are pleased to present to the dialysis community this enhanced version of SC+, which we plan to bring into commercialisation in the second half of 2018.
Alongside the advances we have made at the product level, we have also strengthened Quanta with key additions in our engineering, operations and commercial teams to enable a successful market-launch next year. We are strongly positioned for commercial success, with our pioneering personal haemodialysis system SC+ that is designed to unlock the potential of patient-led care.”
Maddy Warren, Patient Advocate, said: “The number of patients with Chronic Kidney Disease requiring dialysis is going to increase in the coming years, and we currently have a system where the majority are not offered a real choice or flexibility around how they dialyse, leaving them with very little control over their treatment. Patients very quickly become institutionalised, with most believing they have no other treatment options and resigning themselves to a lack of freedom and normality. The whole concept of dialysis, being totally dependent on a machine to keep you alive, can be daunting and overwhelming; physicians need to help give kidney patients confidence that they can take ownership of their treatment and in doing so can greatly improve their quality of life.
I am extremely passionate about home dialysis and truly believe it is the best form of treatment for many kidney patients, and that is why I’m so excited by the potential of SC+ as it empowers patients with the freedom and flexibility to take back control.”
Dr Charlotte Bebb, Consultant Nephrologist at Nottingham University Hospitals NHS Trust and Principal Investigator, said: “The patients who have been treated in Quanta’s pilot studies thus far have been extremely positive about their experience with SC+. In order to improve patient outcomes, and experiences, whilst on dialysis I think it is necessary to give patients, and clinicians, greater flexibility and control of their own treatment. I believe this system has the potential to significantly improve the way haemodialysis patients are currently treated.”
The UK Annual Dialysis Conference theme for 2017 is ‘Dialysis fit for the 21st century’, which focuses on the challenges, improvements and outcomes faced by dialysis patients and clinicians in the UK. Patients, clinicians and researchers will explore and discuss topics of clinical interest, including effective integrated home dialysis models, clinical challenges in dialysis practice and quality improvement.
For more information about Quanta, please contact: John E. Milad, Chief Executive Officer of Quanta on T: +44 (0)1789 400043; E: email@example.com
SC+ is a unique small, simple and powerful haemodialysis system that supports patients across the continuum of care, from the clinic to the home. SC+ provides clinical efficacy and high flow rates compatible with traditional treatment regimens used in-centre. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The small form factor and simple-to-use design are intended to enable a broader range of users across a wide range of settings.
Quanta aims to improve the lives of dialysis patients by providing advanced haemodialysis solutions for use both in the clinic and the home. Quanta’s lead product SC+ is designed to empower dialysis patients by giving them greater flexibility, convenience and control over the delivery of their life-sustaining renal replacement therapy. Quanta is based in Alcester, UK, and was founded in 2008 as a spin out from IMI plc. The company has attracted funding from a group of leading investors, including: Stage Capital (formerly NBGI Ventures), Wellington Partners, Seroba Life Sciences, b to v Partners, ALIAD, Seventure Partners and Kuwait Life Sciences Company, as well as founding partner IMI plc.
For more information, please visit: www.quantadt.com